{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 34,
  "pageCount": 366,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a WSJ article as a source to expose the CEO's attempt to distance himself from a controversial business practice.",
  "elementsJson": [
    "paragraph",
    "headshot",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/34",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-34",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Aronin’s bio’s, websites, and his LinkedIn profile all avoid mention of Marathon Pharmaceuticals, which he founded a decade ago.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccb-6a6a33c9c022",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7944fa47-097b-4990-9971-3bc4ce67bcff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Aronin’s bio’s, websites, and his LinkedIn profile all avoid mention of Marathon Pharmaceuticals, which he founded a decade ago. The company spent $370K to license old clinical data, from the 1990’s in the UK, for a Duchenne Muscular Dystrophy drug called deflazacort, a cheap generic sold for ~$1,000/year, and used it to get FDA approval without running any trials. The day it was approved, Marathon raised the price by ~90 times to $89,000 versus the price US families paid an online UK pharmacy. The WSJ, in a detailed investigative piece, stated “the company didn’t do the late-stage clinical trials needed to win FDA approval to market deflazacort. That step usually is the costliest part of drug development and often cited by companies as a justification for their prices.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fbdea7e-6070-40ed-a6bc-1914b9877bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.75,
        "x": 0.07,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "Sticker shock over $89,000 muscular-dystrophy treatment from Marathon Pharmaceuticals and shame campaign against CEO led to hasty sale",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd062b48-f884-4e7a-9d61-62d8489f199e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“the company didn’t do the late-stage clinical trials needed to win FDA approval to market deflazacort. That step usually is the costliest part of drug development and often cited by companies as a justification for their prices.” — The WSJ",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccb-6f04f9fbf389",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "source-note",
      "text": "WSJ article, 2017",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e4d4fc-ef2d-4fc5-8e4a-d06e2d1a0f67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.65,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "title",
      "text": "Revolt Against Sky-High Drug Prices Prompts a Pioneer to Cash Out",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "338a286b-4e4a-482c-b730-7b4300233ac6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "921e2f65-3a1a-4d77-813f-5268d50a0a89",
      "evidence": "Exposing the CEO's attempt to hide a controversial past business venture.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 50,
      "from": 31,
      "beatId": "2b789ae4-940c-4d3a-9f03-7f2e7e4f46fd",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": null,
      "evidence": "The document presents the struggle of the company's critics and short-sellers to expose the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}